Arasali, Baby Boy .

HRN: 21-35-20  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/24/2022
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
05/24/2022
06/01/2022
IVTT
35mg
Q24
MSAF, Thinly
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Unspecified Sepsis    Compliance to guidelines: Guideline Not Available

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: